source
- Novartis pays $575 million upfront for access to Chinese biotech Abogen’s RNA platform and option on ABO-2203Novartis announced a deal with China‑based Abogen Biosciences that could be worth up to $7.8 billion. The agreement includes an upfront payment of $575 million. Under the deal, Abogen will provide…
- Kodiak Sciences' Zenkuda shows non-inferior six-month dosing vs Eylea, shares doubleFour years ago Kodiak Sciences saw its share price plunge about 80% after its lead eye-disease candidate failed a head-to-head trial against Regeneron's Eylea, wiping out roughly $2 billion in mark…